ZTS logo

Zoetis

ZTS · What the business does, what can go wrong, and how options sellers approach it

What it does

Zoetis develops, makes and sells medicines, vaccines, diagnostics and related products for animals. Its customers care for two broad groups: companion animals (dogs, cats and horses) and production animals (cattle, pigs, poultry and fish raised for food). It was once part of Pfizer and later became an independent public company.

How it makes money

Zoetis sells products mainly through veterinarians, distributors and livestock producers. Revenue comes from several categories: parasite control, vaccines, anti-infectives, pain and dermatology treatments, and diagnostic tools and services. Patent-protected branded products usually carry higher margins, while older products face generic competition. Spending on pets tends to be recurring, since animals need ongoing treatment and preventive care.

Why investors own it

Investors often view Zoetis as a way to own long-term trends in pet ownership and in spending on pet health. Its scale, research pipeline and veterinary relationships can give it an edge. Many of its products are used repeatedly, which can make revenue more predictable than in many other healthcare areas. Some investors also like that it is less tied to human healthcare policy, though it is not immune to regulation.

What can go wrong

  • A key product could lose patent protection or face a strong new rival.
  • Pet owners may cut back on vet visits when budgets get tight.
  • Livestock demand can be hit by disease outbreaks, commodity prices and trade disruptions.
  • Regulators can delay approvals or add safety requirements.
  • Currency swings affect results because it sells globally.

What to watch

  • Growth in the companion animal and production animal segments
  • Sales of its largest branded products
  • Veterinary visit trends
  • Pipeline progress and regulatory approvals
  • Operating margin trends
  • Currency effects on reported results

Options income angle

Options on ZTS are generally available across a range of strikes and expirations, and liquidity is usually decent for a large-cap stock, though less deep than for the most heavily traded names. Implied volatility tends to rise ahead of quarterly earnings, and also around guidance changes, competitive news or regulatory decisions. One caution for anyone selling premium: a sharp earnings-driven move can lead to losses that outweigh the premium collected, so it helps to know whether an option's life spans a report date.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 12, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Zoetis reported revenue of $9,467 million for 2025 and net income attributable to Zoetis of $2,673 million. Growth in pet products was largely offset by a drop in livestock sales tied to a business sale. The company also raised $2.0 billion of convertible notes in December 2025 and used the proceeds mainly to buy back stock. Five products still produce approximately 42% of revenue.

How the business did

  • Revenue rose 2% from $9,256 million in 2024. Net income attributable to Zoetis was $2,673 million versus $2,486 million. Adjusted net income, a non-GAAP measure that strips out items such as purchase accounting, was $2,847 million.
  • Price growth of approximately 4% and volume growth of approximately 1% each from key franchises and other in-line products drove revenue. The sale of the medicated feed additive business (MFA divestiture) took approximately 3% off volume. Cost of sales fell to 28.2% of revenue from 29.4%.
  • Companion animal revenue was $6,587 million, up 5%. Livestock was $2,764 million, down 5%. U.S. revenue of $5,097 million was flat, with lower Librela sales. International revenue was $4,254 million, up 4%.
  • Operating cash flow was $2,904 million versus $2,953 million. The company repurchased 23.9 million shares for $3.2 billion.
  • Management flagged that Q4 2025 International sales were pulled forward by approximately 2.5% to 3.5%, a trend it does not expect to recur.

Risks specific to this company

  • Product concentration: Simparica/Simparica Trio contributed approximately 16% of revenue and Apoquel approximately 12%. The ten top-selling products and product lines contributed 57%, so a safety or competitive problem with one could matter a great deal.
  • Generic competition: Since generics arrived, U.S. sales of Rimadyl chewable and Draxxin have declined by 39% and 66%. The filing says generic competitors are launching at risk, meaning before patent rights expire.
  • Debt: Zoetis had approximately $9.2 billion of unsecured debt, including the new convertible notes. Converting holders must be paid cash for principal, and any excess can be paid in shares, which could dilute existing holders.
  • Antibacterial restrictions: Livestock antibacterials brought in approximately $713 million, and bans or tighter rules in the U.S., EU, U.K., China and Vietnam could reduce demand.
  • Foreign exposure: Approximately 42% of revenue was in currencies other than the U.S. dollar. The company has substantial operations in countries with cash repatriation limits, including China.
  • Tax dispute: The IRS issued a Revenue Agent Report in September 2024 on the one-time mandatory deemed repatriation tax. The company disagrees and says the outcome is uncertain.

What management is watching

  • Fiscal year alignment: Zoetis expects to end the one-month reporting lag for its International subsidiaries in 2026. It has already moved the timing of annual price increases in some markets and delayed processing of certain December 2025 orders into 2026.
  • Systems overhaul: A multi-year ERP (enterprise resource planning) system transition continues. Business process transformation costs were $29 million in 2025 and are described as not expected to recur.
  • Capital return: $2.4 billion remained under the $6 billion share repurchase authorization at year end.
  • Variability factors: Management lists tariffs, distributor inventory stocking, weather, disease outbreaks, inflation and product mix as drivers of results.
  • Measures management points to: These are operational growth (growth excluding currency effects), adjusted net income and adjusted EPS. Adjusted diluted EPS was $6.41 versus $5.92.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 5, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Zoetis reported revenue of $2,391 million for the quarter ended September 30, 2026, down 1% from $2,422 million a year earlier. Net income attributable to Zoetis fell 18% to $591 million, helped little by a weak U.S. pet business and weighed down by restructuring and impairment charges. Livestock and International sales grew, partly offsetting declines in U.S. companion animal (pet) products.

How the business did

  • Quarter: Operational revenue, which strips out currency effects, fell 2%, with about 1% each from lower volume of key franchises, lower net price realization and the divested medicated feed additive business. Adjusted net income, which excludes purchase accounting, deal-related and certain unusual items, was $720 million versus $754 million. Adjusted diluted earnings per share was $1.75 versus $1.70, while the reported figure was $1.44 versus $1.63.
  • Segments: U.S. revenue fell 6%, with U.S. companion animal revenue down $89 million. The filing cites softer demand, competition in dermatology, and generic competition for Convenia and Cerenia. U.S. livestock rose $13 million. International revenue rose 4%, led by cattle and fish products, with launches of Lenivia and Portela, its long-acting pain antibody products, supporting companion animal sales.
  • Year to date: Nine-month revenue was $7,121 million versus $7,094 million. Net income attributable to Zoetis was $1,883 million versus $2,049 million, and adjusted net income was $2,147 million versus $2,178 million.
  • Unusual items: The quarter included $43 million of restructuring and related costs, mostly employee termination costs. Impairment charges on in-process research and development assets acquired from PetMedix in 2023 also hit results. Refunds of prior tariff assessments partly offset costs.
  • Cash and capital return: Operating cash flow for nine months was $1,880 million versus $2,056 million. Zoetis repurchased 17.7 million shares for $1,659 million and paid dividends. $770 million remained under the buyback authorization. Cash and cash equivalents were $1,333 million versus $2,450 million at December 31, 2025.

What management is watching

  • Management lists factors that can make quarterly results uneven, including tariffs, competition, distributor inventory levels, weather, disease outbreaks, and timing changes tied to the Fiscal Year Alignment. This is the 2026 change that ended the one-month reporting delay for international subsidiaries. It also shifted the timing of some International price increases and customer orders.
  • Spending continues on a multi-year business process transformation program, including a new ERP (enterprise resource planning) system, and on a comprehensive cost and productivity program.
  • Management points investors to operational results and adjusted net income, both non-GAAP measures, meaning they are not defined by standard accounting rules.
  • Management says cash, operating cash flow and financing arrangements should cover cash needs for the next twelve months and beyond. No amounts were drawn on the credit facility.

Follow ZTS in Kortex

The Kortex app shows ZTS's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.